Floatz logo

Riluzole

Multiple System Atrophy

King's College LondonSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Multiple System Atrophy cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
ATH-434
Alterity Therapeutics
Phase 2B
IOFLUPANE
GE Healthcare
Phase 3B
Fipamezole
Juvantia Pharma Ltd
Phase 2CCC

View all 40 →

Same molecule, other indications

Riluzole is also rated in:

amyotrophic lateral sclerosisDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
68 / 100
View asset →
cerebellar ataxiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →